All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2025-01-09T14:29:09.000Z

Low-dose ruxolitinib reduces incidence of aGvHD post haplo-HSCT

Jan 9, 2025
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in graft-versus-host disease.

Bookmark this article


A phase III randomized trial (NCT04838704) investigated the efficacy of the addition of low-dose RUX to cyclosporin + MTX vs MMF + CsA + MTX for the prevention of aGvHD post haplo-HSCT.1 Results from the trial were presented by Yanmin Zhao at the 66th ASH Annual Meeting and Exposition.1


Key learnings
The incidence of Grade 2–4 aGvHD was lower in the RUX + CsA + MTX arm vs the MMF + CsA + MTX arm (7.8% vs 36.9%, p < 0.001); MVA also showed a lower incidence of Grade 2–4 aGvHD at Day 100 (HR, 6.07).
RUX + CsA + MTX vs MMF + CsA + MTX showed lower incidence of Grade 2–4 aGvHD at Day 180 (12.6% vs 38.8%, p < 0.001) and moderate-to-severe cGvHD (3.3% vs 19.6%, p = 0.006).
Patients in the RUX + CsA + MTX arm had higher 3-year GRFS (76.5% vs 54.2%, p = 0.00014) and lower 3-year NRM (NR vs 6.0%, p = 0.014) than those in the MMF + CsA + MTX arm.
Based on the findings, low-dose RUX significantly reduced the incidence of both Grade 2–4 aGvHD and moderate-to-severe cGvHD.

Abbreviations: aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; CsA, cyclosporin A; GRFS, graft-versus-host disease relapse-free survival; HR, hazard ratio; MMF, mycophenolate mofetil; MTX, methotrexate; MVA, multivariate analysis; NR, not reached; NRM, non-relapse mortality, RUX, ruxolitinib.

  1. Zhao Y. Oral abstract #1044. A multicenter randomized controlled trial of low-dose ruxolitinib for GvHD prophylaxis in haploidentical hematopoietic stem cell transplantation. 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 9, 2024, San Diego, US. 

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox